Hemispherx: FDA Office Says One Ampligen Issue Addressed

Hemispherx Biopharma said that the Food and Drug Administration’s district office in Seattle has accepted that manufacturing issues regarding the company’s experimental Ampligen drug for chronic fatigue syndrome have been addressed.
Philadelphia Business Journal